[go: up one dir, main page]

BR0112484A - Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo - Google Patents

Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo

Info

Publication number
BR0112484A
BR0112484A BR0112484-6A BR0112484A BR0112484A BR 0112484 A BR0112484 A BR 0112484A BR 0112484 A BR0112484 A BR 0112484A BR 0112484 A BR0112484 A BR 0112484A
Authority
BR
Brazil
Prior art keywords
ester
compound
pharmaceutically acceptable
derivative
acceptable salt
Prior art date
Application number
BR0112484-6A
Other languages
English (en)
Inventor
Takahide Nishi
Toshiyasu Takemoto
Takaichi Shimozato
Futoshi Nara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0112484A publication Critical patent/BR0112484A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/002—Nitriles (-CN)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/008—Preparation of nitrogen-containing organic compounds containing a N-O bond, e.g. nitro (-NO2), nitroso (-NO)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO OU UM SEU SAL, éSTER OU OUTRO DERIVADO FARMACOLOGICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO OU DE UM SEU SAL, éSTER OU OUTRO DERIVADO FARMACOLOGICAMENTE ACEITáVEL, E, PROCESSO PARA A PREPARAçãO DO MESMO". Os compostos da fórmula geral (I) ou seus sais, ésteres ou outros derivados farmacologicamente aceitáveis, que exibem atividades imunossupressivas excelentes em que R1 e R2 são cada um hidrogênio ou um grupo de proteção de amino; R3 é hidrogênio ou um grupo de proteção de hidroxila; R4 é alquila inferior; n é um número inteiro de 1 a 6; X é etileno; Y é alquileno C1-10 que pode ser mono a tri-substituído com um a mais membros selecionados dos grupos a e b de substituintes; R5 é arila; e R6 e R7 são cada um hidrogênio ou um membro selecionado do grupo a de substituintes, com a condição de que quando R5 é hidrogênio, Y é um grupo exclusivo de ligação única e alquileno C1-10 linear.
BR0112484-6A 2000-07-13 2001-07-10 Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo BR0112484A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000212246 2000-07-13
JP2000241744 2000-08-09
JP2000283218 2000-09-19
PCT/JP2001/005988 WO2002006268A1 (en) 2000-07-13 2001-07-10 Amino alcohol derivatives

Publications (1)

Publication Number Publication Date
BR0112484A true BR0112484A (pt) 2003-09-23

Family

ID=27344040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112484-6A BR0112484A (pt) 2000-07-13 2001-07-10 Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo

Country Status (19)

Country Link
US (2) US6723745B2 (pt)
EP (1) EP1300405B1 (pt)
KR (1) KR100812578B1 (pt)
CN (2) CN1328387C (pt)
AT (1) ATE360011T1 (pt)
AU (2) AU2001269503B2 (pt)
BR (1) BR0112484A (pt)
CA (1) CA2415678A1 (pt)
CZ (1) CZ200350A3 (pt)
DE (1) DE60127961D1 (pt)
HU (1) HUP0301688A3 (pt)
IL (3) IL153594A0 (pt)
MX (1) MXPA03000397A (pt)
NO (1) NO20030120L (pt)
NZ (2) NZ523554A (pt)
PL (1) PL359411A1 (pt)
SK (1) SK152003A3 (pt)
TW (1) TWI301833B (pt)
WO (1) WO2002006268A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
CN1328387C (zh) * 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
WO2002029001A2 (en) 2000-10-03 2002-04-11 University Of Virginian Patent Foundation Novel lysophosphatidic acid receptor agonists and antagonists
WO2002064616A2 (en) 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
SK11942003A3 (sk) * 2001-03-26 2004-03-02 Novartis Ag Deriváty 2-aminopropanolu, ich použitie a farmaceutická kompozícia, ktorá ich obsahuje
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
US20040249170A1 (en) * 2002-01-24 2004-12-09 Alfio Borghese Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
RU2358717C2 (ru) * 2002-05-16 2009-06-20 Новартис Аг Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
SE0202280D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
WO2004026817A1 (ja) 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR101095807B1 (ko) * 2002-09-24 2011-12-21 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
EP3075356B1 (en) 2002-11-07 2023-07-05 ConforMIS, Inc. Method of selecting a meniscal implant
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
WO2005005383A1 (ja) * 2003-07-11 2005-01-20 Sankyo Company, Limited アミノアルコール化合物
TW200505416A (en) * 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
DE102004004719A1 (de) 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
TWI355934B (en) * 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
MXPA06012663A (es) 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
EP1750722A4 (en) 2004-05-06 2010-03-10 Univ Virginia NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
KR101174930B1 (ko) 2004-07-30 2012-08-17 노파르티스 아게 ２-아미노-１,３-프로판디올 화합물의 화합물 제제
US7119211B2 (en) * 2004-09-23 2006-10-10 Yamakawa Chemical Industry Co., Ltd. Process for preparing optically active 3-(methylamino)-1-(2-thienyl) propan-1-ol and intermediates for preparation
KR101181090B1 (ko) * 2004-10-12 2012-09-07 교린 세이야꾸 가부시키 가이샤 2-아미노-2-［2-［4-(3-벤질옥시페닐티오)-2-클로로페닐］에틸］-1,3-프로판디올 염산염 또는 그 수화물의 제조방법 및 그 제조 중간체
SG158096A1 (en) 2004-11-29 2010-01-29 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
GB0519274D0 (en) * 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases
PT1932522E (pt) * 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
MY152176A (en) * 2006-08-08 2014-08-15 Kyorin Seiyaku Kk Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
LT3103448T (lt) 2006-09-26 2019-10-10 Novartis Ag Farmacinės kompozicijos, apimančios s1p moduliatorių
TW200906389A (en) * 2007-05-25 2009-02-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising of therapeutic or prophylactic agents for hepatitis
EP3120833A1 (en) 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN103396346A (zh) * 2008-05-19 2013-11-20 杏林制药株式会社 光学活性氨基醇衍生物的制备方法
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
WO2013109991A1 (en) 2012-01-20 2013-07-25 Acucela Inc. Substituted heterocyclic compounds for disease treatment
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817494A1 (de) * 1977-05-03 1978-11-09 Continental Pharma Aminoalkohol-derivat
US4638070A (en) * 1978-12-21 1987-01-20 Continental Pharma Heterocyclic amino-alcohol derivatives
JPS55124742A (en) * 1979-03-20 1980-09-26 Kyowa Hakko Kogyo Co Ltd Novel aminoalcohol derivative
JPS60132934A (ja) * 1983-11-21 1985-07-16 Nippon Shinyaku Co Ltd ブタノ−ル誘導体
GB8405112D0 (en) * 1984-02-28 1984-04-04 Akzo Nv Anti-arrhythmic amino-alcohols
US5250546A (en) * 1984-09-28 1993-10-05 Nippon Chemiphar Co., Ltd. Amino-alcohol derivatives and processes for their preparation
FR2585708B1 (fr) * 1985-07-31 1989-07-07 Sanofi Sa Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique
IL86740A (en) * 1987-06-30 1992-11-15 Tanabe Seiyaku Co Thiphene derivatives,their preparation and pharmaceutical compositions containing them
JPH02256612A (ja) * 1988-12-22 1990-10-17 Tanabe Seiyaku Co Ltd 消化管機能調整剤
JP2747849B2 (ja) * 1990-08-24 1998-05-06 大鵬薬品工業株式会社 ２’―デオキシヌクレオシド類の選択的アシル化方法
ATE141950T1 (de) * 1990-12-24 1996-09-15 Hoechst Ag Verfahren zur acylierung von alkoholen mit einem immobilisierten pseudomonas-lipase
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1993015405A1 (en) * 1992-01-29 1993-08-05 Sci-Clone, Inc. Carcinoma associated antigen (sk1) monoclonal antibodies against sk1, methods of producing these antibodies and use therfor
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
DE69420524T2 (de) * 1993-06-29 2000-02-17 Kaneka Corp., Osaka Verfahren zur herstellung von derivaten von 3-amin-2-hydroxy-4-phenylbuttersäure und 1-nitro-4-phenyl-2-butanol zwischenprodukte
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
CN1160421A (zh) * 1994-10-12 1997-09-24 纳幕尔杜邦公司 制备手性α叔羧酸酯的酶促方法
JPH09124564A (ja) * 1995-11-06 1997-05-13 Nikko Rika Kk 光学活性体混合物ならびにその製造方法
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
CN1224697C (zh) * 1996-05-30 2005-10-26 隆萨股份公司 氨基醇及其衍生物的制备方法
EP1319651B1 (en) 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
US6214823B1 (en) * 1997-10-17 2001-04-10 Merck & Co., Inc. Benzodiazepine derivatives as antiarrhythmic agents
CN1328387C (zh) * 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists

Also Published As

Publication number Publication date
KR20030047988A (ko) 2003-06-18
IL174664A0 (en) 2006-08-20
EP1300405A4 (en) 2004-04-21
NZ533997A (en) 2005-11-25
US20040132784A1 (en) 2004-07-08
CN1267429C (zh) 2006-08-02
HK1051680A1 (en) 2003-08-15
IL153594A (en) 2008-04-13
CN1494540A (zh) 2004-05-05
KR100812578B1 (ko) 2008-03-13
CA2415678A1 (en) 2003-01-10
EP1300405B1 (en) 2007-04-18
CZ200350A3 (cs) 2003-05-14
US20030236297A1 (en) 2003-12-25
ATE360011T1 (de) 2007-05-15
MXPA03000397A (es) 2003-05-27
AU6950301A (en) 2002-01-30
WO2002006268A1 (en) 2002-01-24
IL153594A0 (en) 2003-07-06
CN1328387C (zh) 2007-07-25
DE60127961D1 (de) 2007-05-31
HUP0301688A3 (en) 2006-05-29
HUP0301688A2 (hu) 2003-09-29
EP1300405A1 (en) 2003-04-09
US6964976B2 (en) 2005-11-15
US6723745B2 (en) 2004-04-20
SK152003A3 (en) 2004-07-07
TWI301833B (en) 2008-10-11
NO20030120L (no) 2003-03-11
AU2001269503B2 (en) 2005-02-17
NZ523554A (en) 2004-12-24
NO20030120D0 (no) 2003-01-10
CN1680563A (zh) 2005-10-12
PL359411A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
BR0112484A (pt) Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
BR9806413A (pt) Composto e uso do mesmo
BR0306811A (pt) Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
KR950025025A (ko) 우레아 유도체 및 아실 코엔자임 에이 콜레스테롤 아실트랜스퍼라제(acat)억제제로서의 이의 용도
BRPI0008753B8 (pt) composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
BRPI0015203B8 (pt) derivado de quinazolina, composição farmacêutica, e, uso de um composto
BR0110267A (pt) Inibidores de dipeptidil peptidase iv
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
TR199800147T1 (xx) Farnesil transferaz inhibit�rleri olarak 4-merkaptopirolidin t�revleri.
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
AR001787A1 (es) Un compuesto oxazolidin sustituido particularmenteutil como inhibidor de calpaina y/o catepsina b e n el tratamiento de trastornos neurodegenerativos agudos o cronicos y composiciones farmacéuticas que incluyen dicho compuesto
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
TR199701254T1 (xx) 5-HT al�� inhibit�r�n�n selektif 5-HT1A antagonistiyle kombinasyonu.
UY24429A1 (es) Acetidinas
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
BR9710614A (pt) Esteres arilcicloalcanos carboxìlicos, seu uso, composição farmacêutica e preparação.
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
YU178391A (sh) Jedinjenja 7-acil-3(supstituisanih karbamoiloksi) cefema i postupak za njihovo dobijanje
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.